Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5398_Библиотеки_им_академика_М_И_Перельмана.pdf
Chapter 5
Lipid-Based Drug Delivery Systems: Formulation
and Applications
Pratibha Yadav
Abstract
Lipid-based drug delivery systems (LBDDS) have gained significant attention in the pharmaceutical
industry due to their ability to enhance solubility, bioavailability, and stability of various drugs. This chapter
explores the formulation strategies and applications of LBDDS in drug delivery. The formulation of
LBDDS involves the use of lipids such as triglycerides, phospholipids, and surfactants to create various
formulations such as liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and
lipid-based micelles. These systems offer advantages such as sustained release, targeted delivery, and
protection of drugs from degradation. LBDDS find applications in delivering both hydrophilic and
hydrophobic drugs, including anticancer agents, antimicrobials, anti-inflammatory drugs, and peptides.
This chapter discusses the key formulation techniques, characterization methods, and recent advancements
in LBDDS, highlighting their potential to overcome challenges associated with conventional drug delivery
systems and improve therapeutic outcomes.
Key words Lipid-based drug delivery systems, Self-micro emulsifying dr ug delivery system, Nanostructured lipid carriers, Solid lipid nanoparticles
1 Introduction
In recent years, there has been a surge of interest in lipid-based drug
delivery (LBDD) systems as a possible method for improving the
therapeutic efficacy of numerous drugs [1]. Oral, parenteral, ocular, intranasal, dermal/transdermal, and vaginal routes can be utilized for the administration of lipid-based drug delivery systems
(LBDDS) [
These systems utilize lipid-based carriers to encapsulate and
deliver pharmaceutical compounds, providing numerous advantages such as improved drug solubility, enhanced bioavailability,
and targeted delivery [
include lipid solutions, lipid emulsions, lipid dispersions, selfemulsifying drug delivery systems (SEDDS), and self-micro emulsifying drug delivery systems (SMEDDS) as shown in Fig.
2, 3].
4]. Lipid-based drug delivery systems
89
1. In
90 Pratibha Yadav
Fig. 1 Lipid-based formulations
particular, SEDDS and SMEDDS are isotropic mixtures of lipids,
surfactants, and cosurfactants that can disperse spontaneously in
aqueous media and form fine emulsions (SEDDS) or microemulsions (SMEDDS [
5–8].
Each system possesses unique characteristics that can be customized for different drug classes and delivery routes, allowing for a
wide range of applications. LBDDS has shown significant potential
in various therapeutic areas, including oncology, cardiovascular
disease, infectious diseases, and central nervous system disorders
9]. By improving drug solubility and bioavailability, lipid-based
[
systems can enhance the therapeutic effect of drugs and reduce side
effects. Additionally, they provide targeted and sustained drug
release, allowing for optimized dosing regimens and improved
patient compliance.
This chapter aims to provide an overview of lipid-based drug
delivery systems, their formulation techniques, and their applications in the field of drug delivery. We will explore the advantages
and challenges associated with different lipid-based formulations
and discuss recent advancements in this field. Understanding the
formulation principles and applications of lipid-based drug delivery
systems can contribute to the development of more effective and
efficient drug delivery strategies, ultimately leading to improved
patient outcomes and the advancement of pharmaceutical research
and development.
2 Guidelines for Design of Lipid-Based Formulations
While lipid-based formulations will continue to be an important
tool for formulating poorly soluble drugs, the design of these
formulations can be challenging.
Lipid-Based Drug Delivery Systems: Formulation and Applications 91
In his outstanding review, The recently mentioned seven guidelines for designing lipid-based formulations, which are given below.
1. It is essential to maintain the solubility of the drug in the
formulation, after dispersion, and after digestion.
2. The properties of the colloidal species formed after processing
in the gastrointestinal medium are probably more important
than the properties of the formulation itself in improving
absorption.
3. Higher proportions of lipid (>60%) and lower proportions of
surfactant (<30%) and cosolvent (<10%) generally lead to
more robust drug solubilization after dilution.
4. Medium-chain triglycerides can provide greater solubility and
stability of the drug in the formulation, but long-chain triglycerides facilitate more efficient formation of colloidal lipid
species from bile salts and thus can provide greater
bioavailability.
5. Type IIIB self-emulsifying drug delivery system (SMEDDS)
formulations give lower droplet sizes after dispersion. Still,
they are more dependent on the surfactant properties
employed, and nondigestible surfactants generally give greater
bioavailability.
6. The dispersion of type IV formulations (surfactant/cosolvent)
is probably more effective if two surfactants are used instead of
just one.
7. Type IV formulations can provide increased drug solubility but
must be designed with care to ensure that the drug does not
precipitate after dispersion.
lipid-based oral formulations for poorly soluble medications. As
more experience is gained with the design and use of these formulations and the database of successful formulations grows, it is to be
expected that the design of these formulations will be less empirical
as shown in Table
3 Formulation Strategies
The development of lipid formulations, particularly SEEDS and
SMEDDS, is typically rooted in empirical methods. The effectiveness of a lipid formulation hinges on both the lipid excipients’
characteristics and the compound’s physicochemical properties.
An ideal lipid formulation should effectively dissolve the entire
drug dosage within a single unit and sustain the drug’s solubility
without precipitation within the gastrointestinal tract [
ever, formulating optimization faces additional hurdles due to
These guidelines are important to consider when designing
1.
10]. How-
92 Pratibha Yadav
Table 1
Formulation type
Formulation
type
Excipients Characteristics Advantages Limitations
Type I Oils without
surfactants (e.g., tri-,
di-, and
monoglycerides)
Type II Oils and water
insoluble surfactants
Type III Oils, surfactants, and
cosolvents
limitations in preclinical models and uncer tainties regarding how
these formulations translate to the complexities of lipid processing
in humans (as shown in Fig. 1).
3.1 Lipid Nanoparticles
Lipid nanoparticles, a cutting-edge technology in drug delivery,
offer immense potential in pharmaceuticals. These nanostructures
composed of lipids serve as carriers for therapeutic agents, enhancing their stability and bioavailability [
ity and ability to encapsulate both hydrophilic and hydrophobic
drugs, lipid nanoparticles overcome traditional delivery challenges
11]. They can target specific tissues or cells, reducing systemic side
[
effects. Moreover, lipid nanoparticles facilitate controlled release,
optimizing drug efficacy and patient compliance. Their versatility
extends to genetic material delivery, making them pivotal in gene
therapy. As research progresses, lipid nanoparticles promise revolutionary advancements, reshaping the landscape of medicine and
therapeutics (as shown in Fig.
Non-dispersing,
requires digestion
SEEDS formed without
water-soluble
components
SEDDS/SMEDDS formed
with water soluble or
dispersible components
1).
GRAS,
simple,
good capsule
compatibility
Unlikely to
lose
solvent
capacity
on
dispersion
Clear or
almost
clear
Poor solvent
capacity unless
drug is highly
lipophilic
Rather coarse o/w
dispersion,
digestion likely
but not crucial
Possible loss of
solvent capacity
12].With their biocompatibil-
3.1.1 Solid Lipid Nanoparticles (SLNs)
Solid lipid nanoparticles (SLNs) represent a pioneering approach in
drug delivery, offering a multitude of advantages. These nanostructures, comprised of solid lipids, provide exceptional stability and
biocompatibility. Their small size enables efficient cellular uptake
and distribution, enhancing drug bioavailability [
13]. SLNs exhibit
controlled release properties, ensuring sustained therapeutic levels
and minimizing dosing frequency. With customizable surface modifications, they can target specific tissues or cells, optimizing treatment outcomes [
14]. SLNs also mitigate issues associated with
conventional dr ug formulations, such as poor solubility and
Lipid-Based Drug Delivery Systems: Formulation and Applications 93
systemic toxicity. As a versatile platform, SLNs hold immense
promise across various medical fields, driving innovation in pharmaceutical research and development.
3.1.2 Nanostructured Lipid Carriers (NLCs)
3.2 Liposomes
Nanostructured lipid carriers (NLCs) stand at the forefront of
modern drug delivery systems, harnessing the advantages of both
solid lipid nanoparticles (SLNs) and liquid lipids. This innovative
approach addresses the limitations of SLNs by incorporating imperfect lipid matrices, allowing for higher drug payloads and improved
stability [
13]. NLCs offer enhanced drug loading capacity, con-
trolled release kinetics, and increased drug solubility. Their flexible
structure enables precise customization for targeted delivery, minimizing off-target effects and improving therapeutic efficacy
15]. With their biocompatibility and scalability, NLCs represent
[
a promising avenue for advancing personalized medicine and
addressing complex therapeutic challenges in various fields, from
oncology to dermatology.
Liposomes play a pivotal role in drug delivery systems due to their
unique structure and properties. These lipid-based vesicles consist
of one or more lipid bilayers enclosing an aqueous core, allowing
them to encapsulate both hydrophilic and hydrophobic drugs. The
versatility of liposomes enables them to deliver a wide range of
therapeutic agents, including small molecules, proteins, and nucleic
acids [
16]. One key advantage of liposomes is their ability to
improve the pharmacokinetics of drugs by protecting them from
degradation and clearance mechanisms, thus extending their circulation time in the body [
17]. Additionally, liposomes can target
specific tissues or cells through surface modifications, such as ligand
conjugation or antibody coating, leading to enhanced therapeutic
efficacy and reduced systemic toxicity.
This controlled release profile minimizes fluctuations in drug
concentration, optimizing treatment outcomes and patient compliance. Liposomes serve as versatile and efficient carriers for drug
delivery, contributing significantly to advancements in personalized
medicine, targeted therapy, and the treatment of various diseases,
including cancer, infectious diseases, and inflammatory conditions.
3.2.1 Conventional Liposomes
Conventional liposomes represent a cornerstone in drug delivery
systems, offering versatile solutions for therapeutic applications.
These lipid-based vesicles consist of phospholipid bilayers enclosing
an aqueous core, providing a biocompatible and biodegradable
platform for drug encapsulation [
18]. Conventional liposomes
excel in delivering a wide range of pharmaceutical compounds,
including small molecules, peptides, and nucleic acids. Their ability
to encapsulate hydrophilic and hydrophobic drugs simultaneously
makes them particularly valuable in overcoming drug solubility and
bioavailability challenges [
17, 19].
Moreover, conventional
94 Pratibha Yadav
liposomes can be engineered to target specific tissues or cells
through surface modifications, such as ligand conjugation or antibody attachment, enhancing therapeutic efficacy while minimizing
off-target effects.
Despite advancements in nanoparticle-based drug delivery systems, conventional liposomes remain a widely utilized and effective
tool in pharmaceutical research and clinical practice, driving innovation and facilitating the development of novel therapeutics.
3.2.2 PEGylated Liposomes
PEGylated liposomes represent a significant advancement in drug
delivery technology, where polyethylene glycol (PEG) chains are
attached to the surface of liposomes [
20]. This modification confers
several advantages to liposomal formulations. Firstly, PEGylation
increases liposome stability and circulation time in the bloodstream
by reducing recognition and clearance by the immune system, thus
enhancing drug bioavailability [
21]. Furthermore, PEGylated lipo-
somes can passively target diseased tissues or organs through the
enhanced permeability and retention (EPR) effect, which is particularly beneficial in solid tumors and inflamed tissues [
22] The
stealth properties provided by PEGylation also reduce nonspecific
interactions with blood components, minimizing systemic toxicity
and improving the safety profile of encapsulated dr ugs [
20].
Additionally, PEGylated liposomes can be engineered for controlled release of therapeutic agents, allowing for sustained drug
release at the target site. This controlled release profile enhances
therapeutic efficacy while reducing dosing frequency and minimizing side effects [
24].
Overall, PEGylated liposomes have emerged as a versatile and
effective platform for drug delivery, with applications across various
medical fields, including oncology, infectious diseases, and inflammatory disorders [
23]. Their ability to improve drug pharmacoki-
netics, target specific tissues, and minimize adverse effects
underscores their importance in modern pharmaceutical research
and clinical practice.
3.2.3 Multifunctional Liposomes
Multifunctional liposomes represent a sophisticated approach in
drug delivery, combining various functionalities to enhance therapeutic outcomes [17]. These liposomes are engineered with multiple components, such as targeting ligands, imaging agents, and
therapeutic payloads, to achieve diverse objectives within a single
formulation [
One key
25].
feature of multifunctional liposomes is their ability to
target specific tissues or cells through ligand-receptor interactions
26]. By incorporating targeting ligands onto their surface, such as
[
antibodies or peptides, these liposomes can selectively bind to
receptors overexpressed on diseased cells, improving drug accumulation at the target site while minimizing off-target effects.
Lipid-Based Drug Delivery Systems: Formulation and Applications 95
Multifunctional liposomes can incorporate imaging agents, such as
fluorescent dyes or magnetic nanoparticles, enabling real-time visualization and monitoring of drug distribution in vivo [27]. This
capability facilitates personalized treatment strategies and enhances
the understanding of drug pharmacokinetics and biodistribution.
Additionally, multifunctional liposomes can carry multiple
therapeutic payloads, including chemotherapeutic drugs, nucleic
acids, or immunomodulators, allowing for combination therapy
approaches [
28]. This versatility enables synergistic effects, over-
coming drug resistance mechanisms, and improving therapeutic
outcomes. Multifunctional liposomes can be engineered for stimuli-responsive drug release, where drug release is triggered by
specific stimuli present in the disease microenvironment, such as
pH, temperature, or enzyme activity [
29]. This controlled release
profile enhances drug efficacy while minimizing systemic toxicity.
Overall, multifunctional liposomes represent a promising strategy in drug delivery, offering tailored solutions for personalized
medicine, targeted therapy, and combination treatment regimens
across various diseases, including cancer, infectious diseases, and
inflammatory disorders [
30]. Their multifaceted capabilities hold
great potential for advancing precision medicine and improving
patient outcomes.
3.3 Microemulsions and Self-micro Emulsifying Drug Delivery Systems (SMEDDS)
Microemulsions and self-micro emulsifying drug delivery systems
(SMEDDS) are innovative approaches in pharmaceutical formulation, particularly for enhancing the solubility and bioavailability of
poorly water-soluble drugs [
31]. Microemulsions are thermody-
namically stable colloidal dispersions of oil, water, surfactant, and
co-surfactant. They possess ultrafine droplets (typically less than
100 nm) and are optically transparent. Microemulsions offer advantages such as improved drug solubilization, enhanced permeability,
and ease of manufacturing [
SMEDDS a
ubset of microemulsions specifically designed
re a s
32].
for oral drug delivery. They form spontaneously upon dilution with
gastrointestinal fluids, forming fine oil-in-water emulsions
33]. SMEDDS typically contain a drug dissolved or dispersed in
[
an oil phase, along with surfactants and co-surfactants to stabilize
the emulsion [8]. Upon oral administration, SMEDDS facilitate
drug absorption by promoting micellar solubilization, increasing
drug dissolution rate, and improving lymphatic transport [34].
Both microemulsions
and SMEDDS offer numerous benefits,
including increased drug-loading capacity, enhanced stability, and
improved bioavailability of poorly soluble drugs [
35]. They also
provide flexibility in formulation design, allowing for tailored delivery systems to meet specific drug requirements. They represent
valuable tools in the development of novel phar maceutical formulations for various therapeutic applications.
96 Pratibha Yadav
3.4 Hybrid Systems
Hybrid systems in drug delivery refer to innovative approaches that
combine different delivery platforms or materials to create multifunctional formulations with enhanced therapeutic efficacy and
versatility [
36].
One example of a hybrid system is the combination of liposomes with nanoparticles, where liposomes act as carriers for nanoparticles or vice versa [37]. This hybrid approach harnesses the
advantages of both platforms, such as the targeting capabilities of
liposomes and the controlled release properties of nanoparticles, to
improve drug delivery efficiency and targeting specificity.
Another example is the integration of polymers with lipidbased systems, creating polymeric-lipid hybrid nanoparticles or
micelles [38]. These hybrid systems leverage the biocompatibility
of lipids and the structural versatility of polymers to achieve tailored
drug release profiles, improved stability, and enhanced cellular
uptake.
Furthermore, hybrid systems can involve the incorporation of
targeting ligands, imaging agents, or stimuli-responsive components to impart additional functionalities. For instance, hybrid
systems may incorporate magnetic nanoparticles for magnetic targeting or temperature-sensitive polymers for triggered drug release
in response to external stimuli [
39]. Hybrid systems offer several
advantages, including improved drug solubility, enhanced targeting
specificity, and controlled drug release [40]. They also allow for
synergistic effects between different components, leading to superior therapeutic outcomes compared to individual delivery systems.
3.4.1 Lipid-Polymer Hybrid Nanoparticles
Lipid-polymer hybrid nanoparticles (LPNs) are a versatile class of
drug delivery systems that combine the unique properties of lipids
and polymers [38]. These nanoparticles typically consist of a lipid
core surrounded by a polymeric shell, offering advantages from
both components. The lipid core provides a hydrophobic environment suitable for encapsulating poorly water-soluble drugs,
enhancing their solubility and stability [
41]. Meanwhile, the poly-
meric shell adds structural stability, controlled release properties,
and the ability to functionalize the surface for targeted delivery.
LPNs offer several benefits, including improved drug-loading
capacity, tunable release kinetics, and protection of encapsulated
drugs from degradation [
42]
dditionally, their biocompatibility
. A
and ability to accommodate various drug molecules make them
suitable for a wide range of therapeutic applications.
Further
more, LPNs can be engineered to incorporate stimuliresponsive polymers or targeting ligands, enabling triggered drug
release or specific targeting to diseased tissues, respectively. This
versatility enhances their potential for personalized medicine and
precision therapy [
43]. Their multifunctional nature makes them
valuable tools in pharmaceutical research and clinical practice.
Lipid-Based Drug Delivery Systems: Formulation and Applications 97
3.4.2 Lipid-Protein Hybrid Systems
Lipid-protein hybrid systems represent a novel approach in drug
delivery and biomaterials science, leveraging the unique properties
of both lipids and proteins to create versatile platforms with diverse
applications [
44]. These hybrid systems typically involve the incor-
poration of proteins, such as albumin, into lipid-based carriers like
liposomes or lipid nanoparticles [45]. By combining lipids’ ability
to encapsulate drugs and provide biocompatibility with proteins’
structural diversity and functional properties, lipid-protein hybrids
offer several advantages.
One key advantage is enhanced stability and biocompatibility
conferred by proteins, which can help improve the circulation time
and reduce immunogenicity of lipid-based carriers [46]. Additionally, proteins can facilitate specific interactions with biological targets, enabling targeted drug delivery and tissue-specific uptake
47]. Lipid-protein hybrids can offer unique functionalities by
[
incorporating proteins with inherent biological activity, such as
enzymes or antibodies. This enables the development of therapeutic systems capable of enzymatic drug activation or targeted
immunotherapy.
Furthermore, lipid-protein hybrid systems can be engineered
to respond to external stimuli, such as pH or temperature changes,
allowing for controlled drug release in response to physiological
conditions [
48]. Their versatility and biocompatibility make them
valuable platforms for developing advanced therapeutic strategies
and addressing complex healthcare challenges.
4 Advanced Characterization Methods
4.1 In Vitro and In Vivo Assessment
In vitro and in vivo assessments are fundamental steps in the evaluation of drug candidates and drug delivery systems, providing
valuable insights into their safety, efficacy, pharmacokinetics, and
pharmacodynamics [
conducted outside of a living organism, typically using cell cultures
or isolated tissues. These studies are crucial for preliminary screening of drug candidates, assessing cellular uptake, cytotoxicity, and
mechanism of action. In vitro assays also play a vital role in evaluating the performance of drug delivery systems, such as liposomes or
nanoparticles, including their stability, drug release kinetics, and
targeting efficiency.
In contrast,
living organisms, such as animals or humans [
provide a more comprehensive understanding of drug behavior
within a physiological context, including absorption, distribution,
metabolism, and excretion (ADME) properties. In vivo assessments
also assess pharmacodynamic responses, such as efficacy and toxicity, under physiological conditions.
49]. In vitro assessments involve experiments
in vivo assessments involve studies conducted in
50]. These studies
98 Pratibha Yadav
Integration of both in vitro and in vivo assessments is essential
for comprehensive drug development and translation into clinical
practice [51]. In vitro data provide valuable insights into cellular
mechanisms and initial safety profiling, guiding the selection of
promising drug candidates for further evaluation in animal models
and clinical trials. In vivo studies validate findings from in vitro
experiments, assess systemic effects, and provide evidence of therapeutic efficacy and safety in a physiological context [
52].
Overall, the combination of in vitro and in vivo assessments
enables researchers to gain a comprehensive understanding of drug
candidates and drug delivery systems, facilitating informed
decision-making throughout the drug development process and
ultimately improving patient outcomes.
4.1.1 Dissolution Studies Dissolution studies are essential in pharmaceutical development for
evaluating the rate and extent to which a drug substance dissolves
from its dosage form [
53]. These studies provide critical informa-
tion about drug release characteristics, which directly influence
drug absorption and bioavailability.
In dissolution studies, the drug product is placed in a dissolution apparatus containing a suitable dissolution medium that
mimics physiological conditions, such as pH and temperature.
The dosage form is agitated to ensure uniform drug dissolution,
and samples are withdrawn at specified time intervals [
54]. The
concentration of the drug in the dissolution medium is then
measured using analytical techniques, such as UV-visible spectroscopy or high-performance liquid chromatography (HPLC).
4.1.2 Permeability Studies
Permeability studies focus on assessing the ability of a drug to cross
biological barriers such as cell membranes or the blood–brain
barrier [
55]. These barriers play a significant role in determining a
drug’s bioavailability and distribution within the body. Different
techniques are employed to evaluate permeability, including the
following:
Cell-based assays:
measure the transport of a drug across cell membranes [
Using
cell culture models, researchers can
56]. Tech-
niques like the Caco-2 cell assay simulate intestinal absorption,
providing insights into oral bioavailability and potential drug
interactions.
Art
ificial m
embrane permeability assays: Synthetic membrane
models, such as PAMPA (parallel artificial membrane permeability
assay), mimic biological membranes’ properties and can predict a
drug’s passive diffusion characteristics [
Blood–brain bar
rier (BBB) permeability studies: Understand-
57].
ing a drug’s ability to penetrate the BBB is crucial for central
nervous system (CNS) drug development [
58]. Techniques like
in vitro BBB models and computational modeling help assess
BBB permeability and guide drug design for CNS disorders.